What are the opening hours?

Monday 7am - 3:30pm Tuesday 7am - 3:30pm Wednesday 7am - 3:30pm Thursday 7am - 3:30pm Friday 7am - 3:30pm

Cancer Vaccine Institute - University of Washington

Home
United States
Seattle, WA
Cancer Vaccine Institute - University of Washington

The Cancer Vaccine Institute was previously known as the Tumor Vaccine Group (TVG). (Please do not share health information on this page.

The Cancer Vaccine Institute at the University of Washington is a multidisciplinary group of investigators focused on the diagnosis, prevention and treatment of cancer with novel, immune-based therapies. Involving scientists, doctors, nurses, and patients, our translational research works to bring the most innovative treatments from the bench to the bedside and to harmonize scientific study with patient care. We reserve the right to edit or delete comments.)

07/27/2026

“I think today we’re at a tipping point for cancer vaccines.” - Dr. Nora Disis, Director of the Cancer Vaccine Institute

Dr. Disis recently joined Dr. Katherine Glass at European Medical Journal’s Onc Now podcast to discuss how cancer vaccines are transforming the field of immunotherapy.

From advances in cancer vaccine research to the promise of prevention, Dr. Disis shares how scientists are harnessing the power of the immune system to develop long-lasting immune responses.

Thank you to EMJ and Dr. Katherine Glass for highlighting Dr. Disis’s insights and the promising future of cancer vaccines. Read more and listen to the podcast here: https://www.uwcvi.org/post/that-is-how-fast-science-has-moved-dr-nora-disis-reflects-on-changes-in-cancer-immunology-resear

07/13/2026

The Cancer Vaccine Institute (CVI) is hiring a Research Scientist/Engineer 3 for our Immunologic Monitoring Lab to support cutting-edge cancer immunotherapy research through immunologic assay development, ex*****on, and translational biomarker studies.

As a Research Scientist/Engineer, you will work alongside leading scientists and clinicians to perform advanced immunologic assays, contributing to laboratory operations, troubleshooting and optimizing assay performance, and serving as a technical resource and mentor for fellow team members.

The CVI is looking for candidates with a strong background in cellular immunology and clinical research. If you are passionate about advancing cancer research and improving patient outcomes, we encourage you to apply.

To view more details and submit your application, please visit the University of Washington career site or click here: https://wd5.myworkdaysite.com/recruiting/uw/UWHires/job/Seattle-WA/Research-Scientist-Engineer-3---Department-of-Medicine--Division-of-Hematology---Oncology_REQ-0000134018-1

Help advance the next generation of cancer immunotherapies.

07/10/2026

Meet Dr. Brie Chun, a scientist working to change the future of breast cancer treatment.

As a Principal Investigator at the Cancer Vaccine Institute and a breast oncologist at the Fred Hutchinson Cancer Center, Dr. Chun is dedicated to advancing cancer research and patient care. Her research focuses on improving outcomes for patients with breast cancer, including triple-negative breast cancer (TNBC), one of the most challenging subtypes to treat.

Learn more about Dr. Chun, her journey to the Cancer Vaccine Institute, and her dedication behind her work here: https://www.uwcvi.org/post/on-the-cancer-research-frontier-dr-brie-chun-principal-investigator-and-physician

07/08/2026

“Finance. Focus. Fortitude. Fearlessness.”

These are the four principles necessary to succeed on the cancer vaccine pathway, according to Dr. Nora Disis, Director of the Cancer Vaccine Institute.

In a recent How This Is Building Me podcast episode, Dr. Disis reflects on her career journey, her dedication to cancer research and the promising future of cancer vaccines with host Dr. Ross Camidge.

Thank you to OncLive for hosting this thoughtful conversation. Read more and listen to this episode here: https://www.uwcvi.org/post/onclive-podcast-features-dr-nora-disis-on-leadership-discovery-and-cancer-vaccines

06/24/2026

One of the biggest questions in cancer vaccine research is why some patients develop long-lasting immune protection while others do not.

In a recent commentary, Cancer Vaccine Institute’s Drs. John Liao and Nora Disis highlight two factors that may help predict durable anti-tumor immune responses following therapeutic cancer vaccination.

Patients with pre-existing immunity to the HER2 protein were more likely to develop stronger and longer-lasting HER2-specific T-cell responses after receiving the HER2-targeted vaccine. Additionally, strong T- cell responses just one month after vaccination were a powerful predictor of sustained immunity over time.

Understanding these immune signals could help scientists develop more effective cancer vaccines and may pave the way for more individualized immunotherapy approaches.

Read more here: https://www.uwcvi.org/post/what-makes-a-cancer-vaccine-work-for-years-insights-from-dr-john-liao-and-dr-nora-disis

05/21/2026

The Cancer Vaccine Institute (CVI) is excited to announce that their Phase I trial of the WOKVAC cancer vaccine has been published in the Journal for ImmunoTherapy of Cancer. The study demonstrated that the vaccine is safe, well tolerated, and generates a strong immune response.

WOKVAC is a DNA-based vaccine designed to target three antigens found at abnormally high levels in Ductal Carcinoma In Situ (DCIS), a pre-invasive form of breast cancer that can become invasive cancer in 20% of patients.

In the Phase I trial, patients with non-metastatic breast cancer received three shots of WOKVAC and were followed annually for five years for long-term toxicity.

Results from this study showed that the vaccine was safe and generated the desired anti-cancer immune response. We plan to conduct Phase II clinical trials with WOKVAC for the treatment of DCIS, with the goal of intercepting invasive breast cancer before it develops.

We are one step closer to breast cancer prevention.

Read more here: https://www.uwcvi.org/post/wokvac-phase-i-study-marks-progress-toward-breast-cancer-interception

05/14/2026

Last week, the Cancer Vaccine Institute (CVI) welcomed US Representative Pramila Jayapal (WA-07) for a behind-the-scenes look at how cancer vaccines are the future of cancer treatment and prevention.

During her visit, CVI researchers shared how vaccines are helping train the immune system to treat cancer and prevent recurrence. Congresswoman Jayapal learned how CVI studies suggest that cancer vaccines could intercept cancer at its earliest stages, offering lasting immunity and bringing us one step closer to cancer prevention.

CVI also discussed the importance of sustained public investment in research to help bring accessible, life-saving cancer vaccines to more people. We are working toward a future where cancer prevention becomes a reality.

Read more here: https://www.uwcvi.org/post/inside-the-future-of-cancer-prevention-congresswoman-pramila-jayapal-visits-cvi

05/05/2026

Dr. Nora Disis, Director of the Cancer Vaccine Institute (CVI), joined global leaders in cancer research at the annual American Association for Cancer Research (AACR) meeting.

At the Presidential Select Symposium, “Targeting Stage 0: Precision-Based Prevention,” she presented CVI’s research focused on vaccine-based approaches to prevent cancer.

She focused on preclinical and clinical trials that demonstrated how vaccines can train the immune system to recognize and intercept cancer at its earliest stages by generating T-cells, or immune cells. These immune cells recognize proteins expressed by precancerous and cancerous cells, traveling throughout the body to identify and eliminate abnormal cells.

Dr. Disis also shared updates on CVI’s vaccine-based efforts to intercept Ductal Carcinoma In Situ (DCIS), a form of breast cancer often treated with surgery and radiation, along with preclinical findings on an anti-inflammatory vaccine strategy aimed at reducing obesity-associated cancer risk.

Together, these efforts reflect CVI’s commitment to advancing cancer treatment, prevention, and interception.

Read more here: https://www.uwcvi.org/post/dr-nora-disis-highlights-cancer-prevention-at-the-aacr-presidential-select-symposium

📷 Dr. Disis Headshot Credits: Lisa Stromme Warren

04/30/2026

Earlier this month, Dr. Kiran Dhillon, Executive Director of the Cancer Vaccine Institute (CVI), joined innovators across disciplines at XPRIZE Global Visioneering to solve humanity’s biggest challenges.

Dr. Dhillon participated in the Health domain, focusing on one of the most urgent opportunities in medicine: cancer prevention and treatment. She presented the bold prize concept of vaccines that prevent and treat cancer to the Brain Trust.

The CVI is proud to contribute to this global effort and looks forward to continuing work that brings cancer vaccines closer to reality.

For more details, read here: https://www.uwcvi.org/post/cvi-leaders-join-xprize-global-visioneering-brain-trust

04/23/2026

April 23rd is Husky Giving Day. Join us in the fight against cancer by supporting the Cancer Vaccine Institute (CVI). Your gift helps advance our vaccines designed to prevent and treat some of the most common cancers, including breast, ovarian, colon, lung, prostate, and bladder.

Every contribution moves us closer to a cancer-free future. Give here: https://give.uwmedicine.org/give/?source=NDBCFD&appeal=WEBCVI

Address

Seattle, WA

Opening Hours

Monday	7am - 3:30pm
Tuesday	7am - 3:30pm
Wednesday	7am - 3:30pm
Thursday	7am - 3:30pm
Friday	7am - 3:30pm

Telephone

+18669328588

Website

http://www.uwcvi.org/

Alerts

Be the first to know and let us send you an email when Cancer Vaccine Institute - University of Washington posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cancer Vaccine Institute - University of Washington:

Want your practice to be the top-listed Clinic in Seattle?